SPOTLIGHT: Targeted Genetics study on hold


Seattle-based Targeted Genetics has decided to put its lead drug trial on hold after one of the patients in the study became seriously ill. Researchers have stopped dosing volunteers in the early-stage trial for an experimental therapy for inflammatory arthritis--known as tgAAC94--and patients in the study are being monitored. Analysts noted that it's too early to tell if this is a temporary or permanent setback for Targeted Genetics. Release

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.